For a clinical-stage biotech company, we developed comprehensive revenue forecasts for two lead assets in development as prophylactic treatments for rare blood disorders.

The project involved scenario planning under different market assumptions, testing alternative hypotheses, building detailed patient funneling and segmentation, and developing deterministic and probabilistic models to project revenue streams and assess sensitivity to key variables. We also designed a structured framework to standardize assumptions and update forecasts as new data emerge.

We supported a biotech company at the pre-clinical stage in evaluating the market opportunity and price potential of its lead candidate, developed as a preventive treatment for severe complications following solid organ transplantation.

The assessment included primary research with payer experts to anticipate willingness to pay and identify early pricing benchmarks. We also provided strategic recommendations on clinical trial design to strengthen the future value proposition and improve prospects for market access and reimbursement.

As part of a larger team of consultants, we assisted an established pharmaceutical company in reviewing the value story for a new product indicated for a rare form of autoimmune nephropathy.

As part of a larger team of consultants, we supported an established pharmaceutical company entering the Canadian market

• Health-economic models: We developed a cost minimisation analysis and a budget impact model that were submitted to the Canadian and Québécois authorities
• ITC feasibility assessment: We drafted a statistical analysis plan (SAP) and conducted a feasibility study for a large ITC that included seven different products

As part of a larger team of consultants, we supported an established pharmaceutical company in reviewing the Global Value Dossier and the value story of a drug indicated for a rare vasculitis

• Global Value Dossier: We reviewed and optimized the existing Global Value Dossier, critically assessing the data, refining key messages, and ensuring consistency across the materials
• Global Value Story: We refined the existing value propositions to clearly communicate the unmet need associated with the disease, as well as the product’s clinical and economic benefits
• Cross-functional workshop: We led a cross-functional workshop with stakeholders from market access, marketing, medical, commercial, and senior management to align on key messaging and value strategies

As part of a larger team of consultants, we supported a biotech company developing an FcRn inhibitor for two chronic neuromuscular diseases

• Health-economic models: We developed two cost-effectiveness models comparing the new drug to existing therapies (rituximab, intravenous immunoglobulin, corticosteroids)
• Country adaptation: We helped adapt the models for pricing and reimbursement in France and the UK
• Indirect treatment comparison: We conducted multiple matching-adjusted indirect treatment comparisons to generate comparative evidence of the new intervention vs. existing treatment options

As part of a larger team of consultants, we supported a biotech company in developing a KIT-mutant kinase inhibitor for a rare myeloid neoplasm, which has orphan drug designation in the EU

• Health-economic models: We supported the development of a core cost-effectiveness model comparing the new product to existing treatments
• Country adaptation: We helped adapt the model for reimbursement processes in France, Netherlands, the UK, and Italy (successful reimbursement)
• Analytics: We conducted longitudinal and survival analyses on patient-level data from the pivotal clinical trial

We supported a biotech company developing a new monoclonal antibody for a non-solid tumor. The product was in a Phase IIb clinical trial and had orphan drug designation in the US and EU

• Burden of illness: We estimated the burden of illness associated with the target disease in the US, UK, and Germany
• Cost-effectiveness & budget-impact models: We developed a cost-effectiveness model to compare the new product’s cost-effectiveness to existing treatment options (chemotherapy, CAR-T, HSCT). Additionally, we estimated the product’s budget impact in the UK